Login to Your Account



MNTX Miss in Postoperative Ileus Drops Progenics' Stock

By Jennifer Boggs


Thursday, March 13, 2008
Shares of Tarrytown, N.Y.-based Progenics Pharmaceuticals Inc. lost more than half their value after the company, along with partner Wyeth Pharmaceuticals, reported disappointing Phase III data of methylnaltrexone (MNTX) in postoperative ileus, casting a dark cloud of investor worry over the expansive MNTX program, which includes a pending new drug application for opioid-induced constipation. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription